Ensuring Global Access to Medicines and Vaccines for COVID-19
Are you concerned about COVID-19 and about access and affordability of the vaccines and treatments being developed?
Join Doctors Without Borders/Médecins Sans Frontières (MSF), and Drugs for Neglected Diseases initiative (DNDi) for an online discussion on Thursday May 14 at 1 pm EST, for a deeper look at the need for a widely available COVID-19 vaccine and treatments. Our discussion will also focus on MSF’s work to ensure access and affordability are at the centre of public health research–in Canada and globally–as well as on DNDi’s proven success in providing an alternative non-profit model to develop drugs for the treatment of neglected diseases.
Speakers will include:
Joe Belliveau – Executive Director of MSF Canada
Jason Nickerson – Humanitarian Affairs Advisor at MSF Canada Rachel Cohen – Regional Executive Director of Drugs for Neglected Diseases initiative
We hope to see you there!
Doctors Without Borders/Médecins Sans Frontières (MSF) is a Nobel Prize-winning emergency humanitarian medical organization that has helped tens of millions of people since its founding in 1971. MSF now has more than 40,000 staff members on the front lines of humanitarian crises in close to 70 countries. MSF requires access to affordable and effective medicines in order to help alleviate the suffering of people in need. We also depend on innovations in medical research and development that can address the most life-threatening health risks in the places where we work, which are predominantly low-income countries frequently afflicted by neglected (and often deadly) diseases.
Drugs for Neglected Diseases initiative (DNDi) is a collaborative, patients’ needs-driven, non-profit drug research and development (R&D) organization that is developing new treatments for neglected diseases. Acting in the public interest, DNDi bridges existing R&D gaps in essential drugs for neglected diseases by initiating and coordinating drug R&D projects in collaboration with the international research community, the public sector, the pharmaceutical industry, and other relevant partners to provide an alternative model to develop drugs for these diseases, and ensure equitable access to new and field-relevant health tools.
Click here to learn more.